Myovant Sciences Ltd.
MYOV
MYOV was delisted on the 9th of March, 2023.
34 hedge funds and large institutions have $756M invested in Myovant Sciences Ltd. in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 12 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
31% more capital invested
Capital invested by funds: $575M → $756M (+$181M)
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
19% less funds holding
Funds holding: 42 → 34 (-8)
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$1.95M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$1.76M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$986K |
| 4 |
EU
Emory University
Atlanta,
Georgia
|
+$341K |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$279K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VOYA Investment Management
Atlanta,
Georgia
|
-$4.93M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.17M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$648K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$463K |
| 5 |
Millennium Management
New York
|
-$393K |
MYOV Hedge Fund Activity: Q3 2017 in Review
34 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Myovant Sciences Ltd. (MYOV) for Q3 2017, worth a combined $756M — up 31% from $575M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of MYOV and 4 opened new positions — a net loss of 8 holders — while 10 trimmed existing stakes and 9 added.
The largest buyer was BB Biotech, adding an estimated $1.95M. The largest seller was VOYA Investment Management, exiting entirely with an estimated $4.93M sold.
- 34 institutional investors held Myovant Sciences Ltd. (MYOV) as of Q3 2017, down from 42 in Q2 2017.
- Funds reported $756M of Myovant Sciences Ltd. stock for Q3 2017, up 31% quarter-over-quarter.
- 4 funds opened new Myovant Sciences Ltd. positions in Q3 2017 and 12 closed out, a net change of -8 holders.
- The largest Myovant Sciences Ltd. buyer in Q3 2017 was BB Biotech, an estimated $1.95M added.
- The largest Myovant Sciences Ltd. seller in Q3 2017 was VOYA Investment Management, an estimated $4.93M sold.
Based on aggregated 13F filings for Q3 2017.